Recruitment-status index

RecruitingPeptide Trials.

Explore every peptide study grouped under recruiting in the local registry snapshot. Check the source record before relying on recruitment status, because registry entries can change.

Studies: 434
Recruiting: 434
Completed: 0
Results posted: 1
Countries: 65
Avg enrollment: 398

Velocity

Recruiting trials by start year

Study start year · indexed snapshot

Development

Trials by phase

325phase labels

Early Phase 19

Phase 148

Phase 2135

Phase 391

Phase 442

Industry

Leading sponsors

Novo Nordisk23

Eli Lilly20

Amgen6

Innovent Biologics (Suzhou) Co. Ltd.5

BioMarin4

Hudson Biotech4

Kailera4

Boehringer Ingelheim3

Therapeutic areas

Condition groups

Weight loss100

Type 2 diabetes26

Brain health17

Longevity12

Inflammation11

Pain9

Muscle growth3

Crohn's2

Compound leaders

Most represented peptides.

01Oxytocin34 02Semaglutide33 03Tirzepatide33 04Glucagon31 05Vasopressin31 06Leuprolide29 07Octreotide29 08Goserelin25 09Liraglutide24 10Triptorelin24 11Degarelix21 12Nesiritide17

Study explorer

Search this collection.

434 matching studies

Last registry update first

NCT02960022Phase 2

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

LeuprolideAstellas Pharma Global Development, Inc.Prostate Cancer

Recruiting

Enrollment: 900
Started: Dec 2016
Completion: Jul 2029
Locations: 241
Countries: 38
Updated: Jul 2026

NCT06374875Phase 4

Fibrosis Lessens After Metabolic Surgery

Tirzepatide Semaglutide Liraglutide GlucagonThe Cleveland ClinicMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease

Recruiting

Enrollment: 120
Started: Jul 2024
Completion: Dec 2029
Locations: 22
Countries: 13
Updated: Jul 2026

NCT07619989Not applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

TirzepatideThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolObesity & Overweight

Recruiting

Enrollment: 24
Started: Aug 2026
Completion: Sep 2027
Locations: 1
Countries: 1
Updated: Jul 2026

NCT07673900Phase 1

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

SemaglutideTerrestrial Bio, Inc.Overweight and/or Obesity

Recruiting

Enrollment: 62
Started: Jun 2026
Completion: May 2027
Locations: 1
Countries: 1
Updated: Jul 2026

NCT07740291Not applicable

Tirzepatide Impact Assessment Study

Tirzepatide SemaglutideTexas Tech UniversityObesity & Overweight · Cardiometabolic Health Indicators

Recruiting

Enrollment: 27
Started: Jan 2025
Completion: Dec 2026
Locations: 1
Countries: 1
Updated: Jul 2026

NCT05567198Not applicablePubMed

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

LeuprolideNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Systemic Lupus Erythematosus (Sle) · Primary Ovarian Insufficiency (Poi)

Recruiting